• Aucun résultat trouvé

Operatively induced chronic reflux in rats: A suitable model for studying esophageal carcinogenesis?

N/A
N/A
Protected

Academic year: 2021

Partager "Operatively induced chronic reflux in rats: A suitable model for studying esophageal carcinogenesis?"

Copied!
18
0
0

Texte intégral

(1)

HAL Id: hal-02905869

https://hal.archives-ouvertes.fr/hal-02905869

Submitted on 30 Sep 2020

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of

sci-entific research documents, whether they are

pub-lished or not. The documents may come from

teaching and research institutions in France or

L’archive ouverte pluridisciplinaire HAL, est

destinée au dépôt et à la diffusion de documents

scientifiques de niveau recherche, publiés ou non,

émanant des établissements d’enseignement et de

recherche français ou étrangers, des laboratoires

model for studying esophageal carcinogenesis?

Caroline Gronnier, Emilie Bruyère, Guillaume Piessen, Nicolas Briez, Jérôme

Bot, David Buob, Emmanuelle Leteurtre, Isabelle van Seuningen, Christophe

Mariette

To cite this version:

Caroline Gronnier, Emilie Bruyère, Guillaume Piessen, Nicolas Briez, Jérôme Bot, et al.. Operatively

induced chronic reflux in rats: A suitable model for studying esophageal carcinogenesis?. Surgery,

Elsevier, 2013, �10.1016/j.surg.2013.05.029�. �hal-02905869�

(2)

P-annotatePDF-v11

INSTRUCTIONS ON THE ANNOTATION OF PDF FILES

To view, print and annotate your article you will need Adobe Reader version 9 (or higher). This program is freely available for a whole series of platforms that include PC, Mac, and UNIX and can be downloaded from

http://get.adobe.com/reader/. The exact system requirements are given at the Adobe site:

http://www.adobe.com/products/reader/tech-specs.html.

Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file.

PDF ANNOTATIONS

Adobe Reader version 9 Adobe Reader version X and XI

When you open the PDF file using Adobe Reader, the Commenting tool bar should be displayed automatically; if not, click on ‘Tools’, select ‘Comment & Markup’, then click on ‘Show Comment & Markup tool bar’ (or ‘Show Commenting bar’ on the Mac). If these options are not available in your Adobe Reader menus then it is possible that your Adobe Acrobat version is lower than 9 or the PDF has not been prepared properly.

(Mac)

PDF ANNOTATIONS (Adobe Reader version 9)

The default for the Commenting tool bar is set to ‘off’ in version 9. To change this setting select ‘Edit | Preferences’, then ‘Documents’ (at left under ‘Categories’), then select the option ‘Never’ for ‘PDF/A View Mode’.

(Changing the default setting, Adobe version 9)

To make annotations in the PDF file, open the PDF file using Adobe Reader XI, click on ‘Comment’.

If this option is not available in your Adobe Reader menus then it is possible that your Adobe Acrobat version is lower than XI or the PDF has not been prepared properly.

This opens a task pane and, below that, a list of all Comments in the text. These comments initially show all the changes made by our copyeditor to your file.

(3)

Action Adobe Reader version 9 Adobe Reader version X and XI Insert text

Click the ‘Text Edits’ button on the Commenting tool bar. Click to set the cursor location in the text and simply start typing. The text will appear in a commenting box. You may also cut-and-paste text from another file into the commenting box. Close the box by clicking on ‘x’ in the top right-hand corner.

Click the ‘Insert Text’ icon on the Comment tool bar. Click to set the cursor location in the text and simply start typing. The text will appear in a commenting box. You may also cut-and-paste text from another file into the commenting box. Close the box by clicking on ‘_’ in the top right-hand corner.

Replace text

Click the ‘Text Edits’ button on the Commenting tool bar. To highlight the text to be replaced, click and drag the cursor over the text. Then simply type in the replacement text. The replacement text will appear in a commenting box. You may also cut-and-paste text from another file into this box. To replace formatted text (an equation for example) please Attach a file (see below).

Click the ‘Replace (Ins)’ icon on the Comment tool bar. To highlight the text to be replaced, click and drag the cursor over the text. Then simply type in the replacement text. The replacement text will appear in a commenting box. You may also cut-and-paste text from another file into this box. To replace formatted text (an equation for example) please Attach a file (see below).

Remove text

Click the ‘Text Edits’ button on the Commenting tool bar. Click and drag over the text to be deleted. Then press the delete button on your keyboard. The text to be deleted will then be struck through.

Click the ‘Strikethrough (Del)’ icon on the Comment tool bar. Click and drag over the text to be deleted. Then press the delete button on your keyboard. The text to be deleted will then be struck through.

Highlight text/ make a comment

Click on the ‘Highlight’ button on the Commenting tool bar. Click and drag over the text. To make a comment, double click on the highlighted text and simply start typing.

Click on the ‘Highlight Text’ icon on the Comment tool bar. Click and drag over the text. To make a comment, double click on the highlighted text and simply start typing.

Attach a file

Click on the ‘Attach a File’ button on the Commenting tool bar. Click on the figure, table or formatted text to be replaced. A window will automatically open allowing you to attach the file. To make a comment, go to ‘General’ in the ‘Properties’ window, and then ‘Description’. A graphic will appear in the PDF file indicating the insertion of a file.

Click on the ‘Attach File’ icon on the Comment tool bar. Click on the figure, table or formatted text to be replaced. A window will automatically open allowing you to attach the file. A graphic will appear indicating the insertion of a file.

Leave a note/

comment Click on the ‘Note Tool’ button on the Commenting tool bar. Click to set the location of the note on the document and simply start

Click on the ‘Add Sticky Note’ icon on the Comment tool bar. Click to set the location of the note on the document and simply start typing. Do

(4)

Action

HOW TO...

Adobe Reader version 9 Adobe Reader version X and XI Review To review your changes, click on the ‘Show’

button on the Commenting tool

bar. Choose ‘Show Comments List’. Navigate by clicking on a correction in the list. Alternatively, double click on any mark-up to open the commenting box.

Your changes will appear automatically in a list below the Comment tool bar. Navigate by clicking on a correction in the list. Alternatively, double click on any mark-up to open the commenting box.

Undo/delete change

To undo any changes made, use the right click button on your mouse (for PCs, Ctrl-Click for the Mac). Alternatively click on ‘Edit’ in the main Adobe menu and then ‘Undo’. You can also delete edits using the right click (Ctrl-click on the Mac) and selecting ‘Delete’.

To undo any changes made, use the right click button on your mouse (for PCs, Ctrl-Click for the Mac). Alternatively click on ‘Edit’ in the main Adobe menu and then ‘Undo’. You can also delete edits using the right click (Ctrl-click on the Mac) and selecting ‘Delete’.

SEND YOUR ANNOTATED PDF FILE BACK TO ELSEVIER

Save the annotations to your file and return as instructed by Elsevier. Before returning, please ensure you have answered any questions raised on the Query Form and that you have inserted all corrections: later inclusion of any subsequent corrections cannot be guaranteed.

FURTHER POINTS

x Any (grey) halftones (photographs, micrographs, etc.) are best viewed on screen, for which they are optimized, and your local printer may not be able to output the greys correctly.

x If the PDF files contain colour images, and if you do have a local colour printer available, then it will be likely that you will not be able to correctly reproduce the colours on it, as local variations can occur.

x

If you print the PDF file attached, and notice some ‘non-standard’ output, please check if the problem is also present on screen. If the correct printer driver for your printer is not installed on your PC, the printed output will be distorted.

(5)

Operatively induced chronic reflux

in rats: A suitable model for studying

esophageal carcinogenesis?

Q2 CarolineGronnier, MD,a,b,cEmilieBruyere, PhD,a,b,cGuillaumePiessen, MD, PhD,a,b,c

NicolasBriez, MD,a,b,cJeromeBot, MD,a,b,cDavidBuob, MD,b,d

EmmanuelleLeteurtre, MD, PhD,a,b,dIsabelleVan Seuningen, PhD,a,band

ChristopheMariette, MD, PhD,a,b,cLille, France

Background. The mechanisms of esophageal reflux leading to esophageal adenocarcinoma (EA) remain poorly understood. This study appraises critically an operatively induced chronic reflux rat model. Methods. We randomized 108 Sprague-Dawley rats into 2 experimental groups; one was performing esophagoduodenal (ED) anastomosis with or without gastrectomy to induce duodeno-esophageal reflux (DER group; n = 63), and the other involved duodeno-gastro-esophageal reflux (DGER group; n = 45). Control groups included (i) Roux-en-Y esophagojejunal anastomosis, (ii) laparotomy alone, (iii) subtotal gastrectomy to induce duodenogastric reflux (DGR group), and (iv) the same procedure as in the DGER group plus proton pump inhibition (PPI group). The esophagus underwent histologic and molecular analyses.

Results. The prevalence of Barrett’s esophagus (BE), dysplasia, and EA in the experimental groups was 41%, 7%, and 11%, respectively. Histologic and molecular analyses in groups DER, DGER, and DGR suggested that BE occurred through de novo intestinal metaplasia and proximal migration of duodenal cells. No distant metastases were identified. The molecular characteristics of both BE and EA were similar to humans. BE was more common, and dysplasia and EA less frequent in the DER group when compared with the DGER group (44% vs 24% [ P = .038] and 7% vs 25% [ P = .012], respectively). Compared with the DGER group, carcinogenic sequence occurred less frequently in the PPI-treated group (P = .019).

Conclusion. Despite pathophysiologic differences with humans, the rat model of esophagoduodenostomy reproduces accurately histologic and molecular lesions in the carcinogenetic sequence of BE and allowed us to identify novel, tumor-associated proteins that may be potential biomarkers and new therapeutic targets in EA. (Surgery 2013;j:j-j.)

From Inserm, UMR837,aJean-Pierre Aubert Research Center, Team 5 ‘‘Mucins, epithelial differentiation and carcinogenesis,’’ the Universite Lille Nord de France,bthe Department of Digestive and Oncological Surgery,cUniversity Hospital Claude Huriez, Centre Hospitalier Regional et Universitaire de Lille, and the Centre de Biologie-Pathologie,dDepartment of Pathology, Centre Hospitalier Regional et Universitaire de Lille, Lille, France

DESPITE ADVANCES IN MULTIMODAL THERAPY, the

prog-nosis for invasive esophageal adenocarcinoma (EA) remains poor.1 EA is thought to develop in Barrett’s esophagus (BE), following the low- to high-grade dysplasia sequence and under the

influence of duodeno-gastric-esophageal reflux (DGER).2 The cytotoxic mechanisms of reflux leading to initiation and progression of BE remain poorly understood. The hypothesis has been made that pH changes in DGER caused by PPI may induce cytoxicity related to the bile acid refluxed and may play a role in the increase in incidence of EA incidence in Western countries.3

Because of the long delay in the progression of the carcinogenic sequence in humans, an efficient animal model of BE and EA better our under-standing of the mechanisms involved. Various surgical models of BE/EA have been reported.4-10 None showed superiority. Discrepant results have been reported regarding the time of development

Accepted for publication May 16, 2013.

Reprint requests: Christophe Mariette, MD, PhD, Professor of Surgery, Department of Digestive and Oncological Surgery, University Hospital Claude Huriez, Centre Hospitalier regional et Universitaire, Place de Verdun F-59037, Lille, France. E-mail: christophe.mariette@chru-lille.fr.

0039-6060/$ - see front matter Ó 2013 Mosby, Inc. All rights reserved. http://dx.doi.org/10.1016/j.surg.2013.05.029 SURGERY 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124

(6)

of each step in the sequence of carcinogenesis.11 Whether the metaplasia in these models is de novo, originating from the esophageal glands, is derived by entrapment of duodenal mucosa to the esophageal wall during the anastomosis, or occurs by creeping substitution (proximal migra-tion of duodenal cells through the anastomosis) remains unclear.8,12,13 Doubt has been cast on whether these models reflect the development of BE and EA.8 Moreover, many investigators have also reported adenosquamous or pure squamous cell carcinoma, questioning the model’s ability to elucidate mechanisms of tumorigenesis.9,13Finally, the respective roles of duodenal and gastroduo-denal reflux in the model remain unsolved.5,7 These questions raise the validity of the animal model as a reliable tool in understanding the human carcinogenic sequence.8,12,13

The aims of our study were to evaluate at histologic and molecular levels the (i) value of the rat model, and (ii) respective roles of the duodenal and gastroduodenal reflux, in the BE/EA carcinogenetic sequence.

MATERIAL AND METHODS

Q1

Six-week-old, male Sprague-Dawley rats (Charles River, L’Arbresle, France), were housed under standard laboratory conditions. Operations were performed under general anesthesia, using xylazine (12 mg/kg) and ketamine (80 mg/kg). Through a midline laparotomy, operative proce-dures were performed to induce esophageal reflux. The experimental protocol received approval from the Veterinary Ethics Committee (CREEA, authorization no.59-350177).

Experimental groups (Fig 1). DGER group. We performed

[F1-4/C] an esophagoduodenal (ED) anasto-mosis without gastrectomy to study the impact of the combination of gastric and duodenal reflux on esophageal mucosa. The esophagus was transected proximal to the gastroesophageal junc-tion, and anastomosed to the duodenum with mucosa-to-mucosa apposition with 8 interrupted sutures of 7.0 polypropylene.

Duodeno-esophageal reflux group. We performed an ED anastomosis with gastrectomy to evaluate the impact of the duodenal reflux on esophageal mucosa. A total gastrectomy was performed after ligation of left gastric and short gastric vessels, and the duodenum just distal to the pylorus. The distal esophagus was anastomosed as in DGER group.

Control groups. Roux-en-Y esophagojejunal anasto-mosis group. We performed an esophagojejunal (EJ) anastomosis with jejunal limb without reflux (internal control). The proximal jejunum was

transected 4 cm distal to the duodenojejunal junction and sectioned proximal to the ligature. The distal segment was anastomosed to the distal esophagus via a Roux-en-Y (RY) esophagojejunos-tomy and an entero-entero anastomosis $15 cm distal to the esophagojejunostomy using a 1-layer, running 7.0 polypropylene suture.

Laparotomy group. We performed laparotomy (LAP) only (external control).

Duodenogastric reflux group. We performed a partial gastrectomy respecting the gastroesopha-geal junction, with a proximal gastroduodenal anastomosis. This duodenogastric reflux (DGR) group, in which the esophagus was adjacent to but not part of the anastomosis, acted as a control for the duodenoesophageal reflux (DER) group to evaluate if the origin of esophageal intestinal metaplasia was de novo, originating from the esophagus, or originating from the duodenum through entrapment of duodenal mucosa into the esophageal wall during the ED or creeping of duodenal cells across the anastomosis as a healing process. The stomach was anastomosed to the duodenum via a gastroduodenostomy with 10 interrupted sutures of 7.0 polypropylene.

Proton pump inhibitor group. Rats that underwent the same procedure as in the DGER group received Esomeprazole (Astra-Zeneca, Dunkerque, France), at a dose of 5 mmol/kg via daily gavage from day 1 after the operative procedure. This group was used to evaluate the suppression of the acidic in the gastric reflux in operatively induced DGER rats to evaluate its role on reflux-induced lesions.

Tissue specimens. All animals were weighed weekly. Rats that became ill or lost>15% of their weight were killed. Rats that died before the scheduled date were autopsied.

Animals were killed under general anesthesia to recover tissue samples at 20 weeks for BE lesions, 30 weeks for dysplasia, and 50 weeks for EA.11As a consequence of the intermediate results obtained for the last 55 rats operated, the killing of these animals was delayed to 60, 70, and 80 weeks, to test the hypothesis that a longer duration of exposure to reflux could increase the incidence of each step of the carcinogenic sequence.1After injection of the euthanizing agent T61, the thoracic and abdominal cavities were inspected with an en bloc removal of the esophagus. After longitudinal opening, the esophagus was sectioned into slices of 2- to 3-mm thickness. In rats with visible esophageal tumor, the liver and the lungs were removed to perform a histologic analysis looking for micrometastases.

ARTICLE IN PRESS

FLA 5.2.0 DTD  SEC CODE: OC

n

YMSY3448_proof  12 June 2013  8:13 am  ce

Surgery j 2013 2 Gronnier et al 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246

(7)

Histologic analysis. Histologic analyses were performed by 2 expert pathologists in a double-blinded manner (EL, DB). Tissues were fixed in 10% (w/v) buffered formaldehyde, embedded in paraffin, cut at 4 mm thickness, and applied on SuperFrost slides (Menzel-Glaser, Braunschweig, Germany). Slides were then stained with hemat-oxylin and eosin, Safran, and Astra blue. Lesions were defined as (i) BE, specialized columnar epithelium with cellular characteristics mimicking human BE (intestinal-like cells and Alcian blue-positive goblet cells); (ii) dysplasia, lesions with an increase of the nuclear-cytoplasmic ratio, nuclear atypia, partial loss of cell polarity, and increase in mitotic figures, and (iii) EA, predom-inant component or pure EA with invasion through the basement membrane to surrounding tissues, tumor stroma reaction, increase in nuclear atypia, and mitotic figures.

pH-metry. A measurement of intragastric pH was performed using a pH meter orion 2 star (Thermoscientific, Brebieres, France), in 10 randomly selected rats of the DGER, LAP, and PPI groups after aspiration through a gastrotomy to assess the persistence of acid secretion (DGER group) or its suppression (PPI group).

RNA extraction and purification. Total RNA was isolated and purified from tissues using the NucleoSpin RNA L kit (Macherey-Nagel, D€uren, Germany) as described in the manufacturer’s protocol. The RNA quantity was determined by measuring the optical density at 260 nm with a NanoDrop 1000 spectrophotometer (Thermo Scientific, Pittsburgh, Penn).

Quantitative reverse transcriptase-polymerase chain reaction. Total RNA (0.5 mg) was used to prepare cDNA using the RT2 First Strand Kit (SABioscience, Valencia, Calif). Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed on cDNA (1 mL), using specific primers for TFF2 (PPR48691A), TFF3 (PPR52672A), Muc1 (PPR51463A), Muc4 (PPR47950A), Nfkb1 (PPR42746A), and Pik3cg (PPR56854A) synthesized by SABioscience and the RT2Fast SYBR Green Master Mixes/fluorescein qPCR Master Mixes. For each of those primers, the standard curve was made to determine the best concentration of cDNA to use. Amplification was made in triplicate for each sample, and the internal control used was the lactate dehydrogenase A (Ldha) gene (PPR56603B). Amplification was made using the CFX96 thermocycler (BioRad, Marnes-la-Coquette, France): 1 cycle of 10 minutes at 958C, followed by 45 cycles of 15 seconds at 958C and 1 minute at 608C.

pH-metry. A measurement of intragastric pH was performed using a pH meter orion 2 star (Thermoscientific, Brebieres, France), in 10 randomly selected rats of the DGER, LAP, and PPI groups after aspiration through a gastrotomy to assess the persistence of acid secretion (DGER group) or its suppression (PPI group).

RNA extraction and purification. Total RNA was isolated and purified from tissues using the NucleoSpin RNA L kit (Macherey-Nagel, D€uren, Germany) as described in the manufacturer’s protocol. The RNA quantity was determined by measuring the optical density at 260 nm with a NanoDrop 1000 spectrophotometer (Thermo Scientific, Pittsburgh, Penn).

Quantitative reverse transcriptase-polymerase chain reaction. Total RNA (0.5 mg) was used to prepare cDNA using the RT2 First Strand Kit (SABioscience, Valencia, Calif). Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed on cDNA (1 mL), using specific primers for TFF2 (PPR48691A), TFF3 (PPR52672A), Muc1 (PPR51463A), Muc4 (PPR47950A), Nfkb1 (PPR42746A), and Pik3cg (PPR56854A) synthesized by SABioscience and the RT2 Fast SYBR Green Master Mixes/fluores-cein qPCR Master Mixes. For each of those primers, the standard curve was made to deter-mine the best concentration of cDNA to use. Amplification was made in triplicate for each sam-ple, and the internal control used was the lactate dehydrogenase A (Ldha) gene (PPR56603B). Amplification was made using the CFX96 thermo-cycler (BioRad, Marnes-la-Coquette, France): 1 cycle of 10 minutes at 958C, followed by 45 cycles of 15 seconds at 958C and 1 minute at 608C.

RT-PCR. Total RNA (1mg) was used to prepare cDNA using oligod(T) (1 mL) and recombinant Retro-Transcriptase Moloney Murine Leukemia Virus (1 mL; Promega, Charbonnieres, France). PCR was performed on cDNA (5mL), using specific pairs of primers: b-actin (sense: ATATCGCTGC GCTCGTCGTCGACAA; anti-sense: AACACAGCC TGGATGGCTACGTACAT), cyclin D1 (sense: TGA CTGCCGAGAAGTTGTG; anti-sense: GAGGGTG GGTTGGAAATG), ErbB1 (sense: AGTGGTC CTTGCAAACTTGG; anti-sense: TTAACTCAAGCT GCCTCGCC), cyclo-oxygenase-2 (sense: AGTAT CAGAACCGCATTGCC; anti-sense: TAAGGTTT CAGGGAGAAGCG), PI3K (sense: GAAGCCATT GAGAAGAAAGGA; anti-sense: GAGGTGTTCAG TATTATCAGAGC), NF-kB (sense: GAAGAAGCGA GACCTGGAG; anti-sense: TCCGGAACACAATG GCCAC), Smad4 (sense: CATTCCTGTGGCTTC CACAA; anti-sense: GACTGATGGCTGGAGCTATT) Surgery Volumej, Number j Gronnier et al 3 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370

(8)

Fig 1. Macroscopic aspect of specimens classified according the operation group and histologic observation of the esophagus after operation using hematoxylin and eosin, Safran, and Astra blue stainings. The control groups with no reflux---(A) LAP and (B) RY groups---showed thin and noninflamed esophagus. (C) In the DGER group, the esophagi were dilated and inflamed, sometimes with the presence of a macroscopic tumor always localized in the distal

ARTICLE IN PRESS

FLA 5.2.0 DTD  SEC CODE: OC

n

YMSY3448_proof  12 June 2013  8:13 am  ce

Surgery j 2013 4 Gronnier et al 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494

(9)

and vascular endothelial growth factor (sense: ACG AAA GCG CAA GAA ATC CC; anti-sense: TTA ACT CAA GCT GCC TCG CC; MWG-Biotech, Ebersberg, Germany). For each gene, analyses were made from $3 different rats. Rat b-actin was used as the internal control. PCR products (20 mL) were separated on a 1.5% (w/v) agarose gel containing ethidium bromide run in 1X Tris Borate EDTA buffer. The gene of interest/b-actin ratio was calculated after scanning DNA bands with GelAnalyst-GelSmart software (Claravision, Verrieres Le Buisson, France).

Microarray analysis. Complementary RNA was synthesized from total RNA and purified using the TrueLabeling-AMP 2.0 Kit and the ArrayGrade cRNA Cleanup Kit respectively (SABioscience), together with biotin-UTP (Roche, Neuilly-sur-Seine, France) according to the manufacturer’s instructions. Complementary RNA (2 mg) was incubated with Oligo GEArrays (SABioscience)---Rat Cancer PathwayFinder, (SABioscience)---Rat Tumor Metastasis, Rat Cell Cycle, and Rat PI3K-AKT signaling pathway microarrays---all designed for profiling the expres-sion of 113 genes. Expresexpres-sion level of each gene was detected by chemoluminescence using ECF substrate on a Storm 860 scanner (GE Healthcare Buckinghamshire, UK; IFR114/IMPRT, U. Lille 2). Signals were analyzed finally with the GEArray Expression Analysis Suite (SABioscience).

Immunohistochemistry. Protein expression was studied using either manual or automatic immuno-histochemistry (IHC). Automatic IHC with an automated 8 immunostainer (ES, Ventana Medical System, Illkirch Graffenstaden, France). Antibodies were purchased from Cell Signaling (Danvers, Mass; cyclin D1 [2926 at 1/50e]), Santa Cruz Biotechnology [Santa Cruz, Calif; MCM6 [sc-9845 at 1/100e], Mmp3 (sc-31074 at 1/100e), Mmp7 (sc-8832 at 1/50e), Mmp10 (sc-6842 at 1/200e), and Timp1 (sc-6834 at 1/100e)]. Positive controls were included by staining normal rat tissues known to express the protein of interest and negative controls were run with 13 D-PBS instead of primary antibodies.

Cell culture. The OE33 EA esophageal adeno-carcinomatous cells were purchased from the

European Collection of Cell Culture and cultured as described in Mariette et al.14

Small interfering RNA assays. Parental OE33 cells were transfected with small interfering RNA (siRNA) from Dharmacon (Epsom, United Kingdom) following the protocol described by Piessen et al.15

Proliferation. Cell proliferation was analyzed by counting cells on a Malassez counting chamber. OE33 cells transfected with siRNA were plated on 24-well plates then counted during 3 days after transfection.

Migration. Cell migration was studied by a wound healing test. Cells were plated on 96-well plates until confluence; a ‘‘wound’’ was then performed using the 96-pin WoundMaker (Essen Bioscience, Ann Arbor, Mich). Plates were placed in an incubator with 5% of CO2 at 378C into the Incucyte device (Essen Bioscience). Every other hour, a picture of the wound was taken and the percentage of wound closure was then every 12 hours, from 0 to 48 hours.

Statistical analysis. The primary objective was the occurrence of $1 element of the carcinoge-netic sequence (either BE, dysplasia, or EA). Based on preliminary experiments and the literature, we hypothesized that with a power of 80% and an a value of 5%,$45 animals per experimental group (DGER and DER groups) were required to observe an incidence of 40% in 1 group versus 75% in the other group (bilateral comparison of 2 binomial proportions). Because intermediate analysis showed a mortality rate of #60%, the number of rats required per group was 120. Statistical analysis was performed using SPSS version 15.0 software (SPSS, Chicago, Ill). Data are shown as prevalence and mean values (standard deviation). Continuous data were compared by means of the Mann– Whitney U test and ordinal data by the Chi-square test or Fisher exact test as appropriate. All statistical tests were 2-sided.

RESULTS

Global evaluation. Among 285 rats operated, 120 were included in the DGER group and 120 in

portion of esophagus exposed to the reflux. The histologic observations showed (D) esophagitis (original magnifica-tion,3200). (E) Esophageal adenocarcinoma with the presence of mucus lakes stained in blue (black arrow; original magnification, 3200) compared with (D, insert) normal esophagus (original magnification, 3200). (F) Operative procedures and compositions of reflux for each group. DGER group, duodeno-gastro-esophageal reflux group allows the induction of a mixed gastric and duodenal reflux in the distal portion of the esophagus; DER group, duodeno-esophageal reflux only in the distal portion of the esophagus; RY group, internal control; LAP group, external control: DGR group, control for the DER group and PPI groups, which allows inhibition of acidic component of the gastric reflux.

=

Surgery Volumej, Number j Gronnier et al 5 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618

(10)

the DER group. The overall mortality rate was 53% and decreased during the study period from 68% to 37%; 55 rats died from respiratory failure owing to massive aspiration (none in the no-reflux groups). Other causes of death were malnutrition (loss of weight> 15%; n = 62), peritonitis (n = 9), intraoperative complications (n = 20), and unknown causes (n = 5). Number of survivors analyzed was 63 in the DGER group, 45 in DER the group, 6 in the DGR group, 10 in the PPI group, 7 in the RY group, and 3 in the LAP group. Nutritional status. The body weight loss was 10 ± 4% and was maximal after 3 weeks. After an initial postoperative decrease, the curve of animal body weight joined progressively the one of the control group (data not shown), suggesting that nutritional status did not interfere with the results observed.

pH-metry. The mean values of the intragastric pH were 2.7 ± 0.4, 2.8 ± 0.4, and 5.1 ± 0.4 in the DGER, LAP, and PPI groups, respectively. This underlines the expected persistence of acid gastric secretion in the DGER group and a decrease in acid secretion after PPI administration (P = .019), which validates the models used to generate both duodenal and gastroduodenal refluxes.

Reflux lesions. In the LAP and RY groups (Fig 1,F), all rats had normal esophagus on macro-scopic (Fig 1,A and B) and microscopic examina-tion (Fig 1,D). In the DGER, DER, DGR, and PPI groups (Fig 1, F), the esophagus was dilated and markedly shortened in all rats, and microscopic analysis showed esophagitis (Fig 1, D). These re-sults attest the efficacy of this chronic reflux model to induce esophagitis.

Steps of the carcinogenetic sequence. In the LAP and RY groups (Fig 1,A and B), no lesions of the carcino-genetic sequence were found. In the reflux groups,

32 animals exhibited visible tumor growth localized on the external surface of the esophagus (Fig 1,C). Histologic analysis in the experimental groups showed at least 1 step of the carcinogenetic sequence in 50% of rats (Table I). Prevalence of ½T1

BE, dysplasia, and cancer were 41% (n = 44), 8% (n = 9), and 11% (n = 12), respectively. Histologic lesions were always observed in the distal esoph-agus, which was the region with maximal exposure to reflux. Among 32 macroscopic tumors, only 12 were histologically proven carcinomas (Fig 1, E), the 20 remaining cases showing only a granulomatous inflammatory reaction. The posi-tive predicposi-tive value of a macroscopic examination in predicting a cancerous lesion was only 38%. This finding suggests that exposure to chronic reflux promotes the development of elements of the carcinogenic sequence in half of the animals.16 Histologic tumor characteristics. Among the proven carcinomas, 8 were well-differentiated, mucinous adenocarcinomas (malignant infiltrating glands associated with lakes of extracellular mucus;

Fig 1, E). Five rats developed adenosquamous carcinomas combining components of squamous carcinoma and adenocarcinoma, but in all carci-nomas, adenocarcinoma was the major compo-nent. Some of these cases exhibited vascular invasion, confirming their malignant nature. Neither lymph node nor distant metastases were identified macroscopically during necroscopies. In rats with visible esophageal tumor growth, a systematic, histologic analysis of the liver and the lungs did not exhibit any micrometastatic dissemi-nation. Even if features of local esophageal malignancy were present, these results challenge the ability of these tumors to metastasize.

Characterization of the intestinal lesions. The IHC analysis showed that intestine-specific markers Table I. Number of rats analyzed: Histologic analysis of resected esophagus of rats, analyzed according to the treatment group

Group

Experimental groups Control groups

DGER group DER group DGR group PPI group RY group LAP group Reflux composition Gastric

duodenal

Duodenal Duodenal Gastric nonacid duodenal No reflux No reflux No. of rats 63 45 6 10 7 10 Histologic results* Esophagitis 63 (100%) 45 (100%) 6 (100%) 10 (100%) 0 (0%) 0 (0%) BE 23 (36%) 21 (47%) 1 (16%) 1 (10%) 0 (0%) 0 (0%) Dysplasia 7 (11%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) EA 8 (13%) 4 (9%) 1 (16%) 0 (0%) 0 (0%) 0 (0%)

*Some rats may exhibit concomitant steps of the carcinogenetic sequence.

BE, Barrett’s esophagus; DER, duodeno-esophageal reflux; DGER, duodeno-gastro-esophageal reflux; DGR, duodeno-gastric reflux; EA, esophageal adenocarcinoma; LAP, laparotomy; PPI, proton pump inhibitor; RY, Roux-en-Y.

ARTICLE IN PRESS

FLA 5.2.0 DTD  SEC CODE: OC

n

YMSY3448_proof  12 June 2013  8:13 am  ce

Surgery j 2013 6 Gronnier et al 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742

(11)

such as Villin, Cdx-2 (data not shown), and Muc2 (Fig 2,

[F2-4/C] A), were expressed in BE, whereas they were never expressed in normal esophagus (data not shown). Expression of cytokeratins 4 (CK4) and 14 (CK14), known to participate in the cytoskel-eton formation and usually found in normal esophageal epithelium, in the cytoplasm of the suprabasal cells for CK4 and of the basal cells for CK14, was also assessed. They were expressed in the histologically normal rat esophagus without expression in BE lesions (data not shown). These results confirm the differentiation of normal esophageal cells submitted to reflux into an intestinal-type phenotype mimicking human BE.

Origin of the intestinal mucosa. To investigate the origin of BE lesions observed in the reflux groups, we went expanded our histologic analysis. Villi and Br€unner glands were present in the esophageal wall, 2 histologic characteristics of normal duodenum, usually not present in human BE (Fig 2, B and C). These results suggest that BE lesions in the ED rat model may not be true BE lesions originating de novo from the esophagus, but may be caused by mechanically induced

entrapment or creeping. To validate these, a histo-logic reassessment of rats with BE was performed. A short segment of BE surrounded by squamous mucosa corresponding to a typical aspect of entrapment was found in 1 rat (Fig 2,D). Second, another control group was constructed by per-forming a subtotal gastrectomy and gastroduo-denal anastomosis (DGR group) in which the esophagus did not form part of the anastomosis. As presented in Table I, esophagitis was present in all these rats, confirming the presence of reflux. One rat developed a mucinous adenocarcinoma arising directly from the anastomotic site and located between the remaining stomach and lower esophagus with surrounding BE lesions. In the absence of histologic lesions in the esophagus, this group did not allow us to eliminate the hypothesis of creeping. Expression pattern of genes encoding trefoil factors (TFF) in BE had been shown previously to differ from that in normal jejunal mucosa in an EJ rat model,17 suggesting that BE lesions represented de novo BE and not creeping; therefore, we studied the expression of TFF-2 and TFF-3 mRNA

Fig 2. Histologic analyses showing the presence of intestinal tissue in the esophagus exposed to reflux. (A) Immuno-histochemistry (IHC) using an anti-MUC2 antibody. (B) Lysozyme staining shows presence of villi (arrows). (C) IHC carried out with an anti-MUC4 antibody shows presence of Brunner’s glands (arrow). (D) Typical aspects of entrapment characterized by a short segment of Barrett’s esophagus surrounded by squamous mucosa. IHC staining was performed using an anti-MUC4 antibody. (A, original magnification, 3200; B, original magnification, 3400; C, D, original magnification,3100). Surgery Volumej, Number j Gronnier et al 7 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864

(12)

by qRT-PCR in BE and normal duodenum. The expression of TFF-2 was more prominent in BE compared with duodenum (1,030-fold), whereas expression of TFF3 was more uniform in the tissues and was not discriminant (1.6 fold; data not shown). Altogether, these data suggest that, in this ED model, BE lesions may occur through various concomitant mechanisms, including de novo intestinal metaplasia and proximal migration of duodenum.

Characterization of the esophageal adenocarcinoma-tous lesions. We sought to evaluate the similarities of tumors found in humans and in this model. The expression of genes and proteins associated with EA tumorigenesis,18,19 and/or implicated in mediation of the effects of bile acid in EA20 was compared in normal esophageal mucosa (no-reflux control groups) and in EA. Having previously shown that membrane-bound mucins MUC1 and MUC4 are overexpressed in human EA and that they are regulated by bile acids,15,20 we showed that genes encoding Muc1 and Muc4 mucins were overexpressed in EA (Fig 3,

½F3 A), as

well as at the protein level (data not shown). We evaluated also expression of transcription factors associated with esophageal tumorigenesis21 or implicated in MUC1 or MUC4 regulation by bile acids,15,20 (Fig 3, B, C and D). A neo-expression of Smad4 (transforming growth factor-b pathway) and cyclo-oxygenase-2 (inflammation) was observed in EA compared with RY controls (Fig 3,B). An increase of the cell-cycle factor cyclin D1 and the epidermal growth factor receptor ErbB1 (cell proliferation), nuclear factor (NF)-kB (inflammation), and vascular endothelial growth factor (angiogenesis) was also found (Fig 3, C). By qRT-PCR, we confirmed the activation of 2, cen-tral signaling pathways in EA tumor progression: NF-kB and PI3K (Fig 3, D). Hnf-1a and Hnf-4a

transcription factors were not expressed in the esophagus of the RY and LAP groups, whereas nuclear expression was found in EA lesions. Nuclear expression of P63 protein was found in the esophageal epithelium of RY and LAP groups and was lost in EA (data not shown). Nuclear expression of Ki-67 (proliferation) was observed

Fig 3. Gene expression in control squamous esophagus (Roux-en-Y [RY] and [LAP] groups) and in esophageal adenocarcinoma (EA). (A) Upregulation of Muc1 and Muc4 in EA compared with RY by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Expression levels are normalized to Ldha and compared with the RY group. (B) Neo-expression of Smad4 and Cox-2 in EA compared with RY and LAP groups by RT-PCR. (C) Upregulation of cyclin D1, ErbB1, NF-kB, and Vegf in EA compared with control groups using RT-PCR. The internal control used wasbactin. (D) Activation of Pi3k and NF-kb associated with the tumor progression in esophagus subjectedQ3

to reflux by qRT-PCR. Expression levels are normalized to Ldha and compared with the RY control. (E) Proliferation and (F) migration assays on OE33 cells transfected with PI3K or NF-kB small interfering RNA (siRNA). Controls are made by a transfection with a non-targeting (NT) siRNA or with the transfection agent alone (mock). *P # .05; **P# .005.

ARTICLE IN PRESS

FLA 5.2.0 DTD  SEC CODE: OC

n

YMSY3448_proof  12 June 2013  8:13 am  ce

Surgery j 2013 8 Gronnier et al 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988

(13)

in the basal layer of the normal esophageal epithelium in the RY and LAP groups and in EA lesions (data not shown). After studying genes known to participate in esophageal carcinogenesis, we then searched for new factors using a transcrip-tomic approach (Fig 4

[F4-4/C] ). As above, genes known to participate in proliferation (cyclin D1) and metas-tasis formation or invasion (Mmp3, -7, -9, -10, -13, the metalloproteinase-inhibitor Timp1) were upre-gulated in EA. Conversely, tumor suppressor genes (Tp53, Tsg101, Pten) and genes participating in cell death (CHEK2, Caspase 9) were down-regulated (Fig 4,A). Alteration of gene expression was confirmed at the protein level by IHC for some of the markers (Fig 4, B). We then focused on 3 genes---CHEK2, TSG101, and MCM6---not yet known to participate in esophageal tumor progression, but known to play roles in epithelial tumorigenesis.21-23 Using small interfering RNA approach, mRNA expression of CHECK, TSG101, and MCM6 was knocked down (KD) in OE33 cells

(Fig 5). Decreased proliferation was observed ½F5 for the 3 KD cell lines as soon as day 2 for MCM6-KD cells (D2, P = .0309; D3, P = .0019) and as of day 3 for CHEK2-KD and TSG101-KD cells (D3, P < .0056 for both). No difference in cell migration was found in CHEK2-, TSG101-, or MCM6-KD cells compared with controls (Fig 5). These data indicate that tumor progression is induced by chronic reflux with activation of key signaling pathways and expression of tumor-associated proteins in a similar way in the DGER and DER groups. These results demonstrate that BE and EA present similar molecular characteris-tics in both experimental groups compared with humans.

Role of exposure time in esophageal carcino-genesis. The prevalence of histologic lesions did not differ between the different times of exposure to reflux (esophagitis, P = .612; BE, P = .195; dysplasia and EA, P = .741). No differences were found when comparing time of reflux exposure

Fig 4. Expression of genes associated with tumorigenesis in esophagus subjected to reflux. (A) Expression of genes using microarrays. Average of 5 different rats showing esophageal adenocarcinoma lesions. (B) Expression of proteins (immunohistochemistry) for which genes were up-regulated in microarrays studies. Normal squamous esophagus (original magnification,3100); esophageal adenocarcinoma (original magnification, 3100; insert, original magnifica-tion,3200). Surgery Volumej, Number j Gronnier et al 9 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110

(14)

to promote $1 step of the carcinogenetic sequence between the DGER and DER groups (median times, 50 [range, 22–68] vs 50 [22–83] weeks; P = .789; Table II

½T2 ). Subgroup analysis in

the DGER and the DER groups showed similar results (P = .741). These findings suggest that esophageal carcinogenesis is not linked to exposure time to reflux and that delaying necroscopy to>50 weeks is useless.

Role of the reflux composition on esophageal carcinogenesis. The proportion of rats who developed $1 step of the carcinogenic sequence did not differ between the 2 groups (49% vs 51%; P = .841). BE lesions were more frequent in the DER group compared with the DGER group (44 vs 24%; P = .038). Prevalence of dysplasia and/or EA lesions was less in the DER group (7%, vs 25%; P = .012). These results suggest that the duodenal component of the reflux may play an initiating role in the carcinogenic sequence, whereas duodenogastric juice may lead to progression of the carcinogenic sequence to EA.

Impact of acid component of gastric reflux. To determine the role of acid component in these findings, the control PPI group (n = 10) was constructed. Macroscopic and histologic results are presented inTable I. At 30 weeks, the esopha-geal macroscopic appearance was similar in the

PPI (n = 10) and in the DGER groups (n = 19), with esophagitis present in all rats. At least 1 step of the carcinogenetic sequence was observed more frequently in the DGER group (58%) compared with the PPI group (10%; P = .019). These results suggest that the acidic reflux may favor progression of the carcinogenic sequence toward EA.

DISCUSSION

Our rat model using either ED or EJ anasto-mosis is considered the most promising model for reproducing histologic lesions mimicking the human EA carcinogenic sequence,3but few groups have characterized the lesions that develop at both the histologic and molecular levels.8,13,24,25 This lack of in-depth characterization of this frequently used model led us to determine whether the rat model reliably and accurately reproduces the carcinogenic sequence as occurs in humans.8,12

We demonstrated herein that the ED rat model of reflux allows the development of metaplasia-like lesions (BE) and its transformation into dysplasia and EA with similar histologic and molecular characteristics described in humans. We showed that the duodenal component of the reflux plays a crucial role in initiating the carcinogenic sequence, whereas duodenogastric juice may lead

Fig 5. Proliferation and migration assays on OE33 cells transfected with MCM6, CHEK2, or TSG101 siRNA. Controls EQ1 are made by a transfection with a non-targeting (NT) siRNA or with the transfection agent alone (mock). *P# .05; **P# .005.

ARTICLE IN PRESS

FLA 5.2.0 DTD  SEC CODE: OC

n

YMSY3448_proof  12 June 2013  8:13 am  ce

Surgery j 2013 10 Gronnier et al 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234

(15)

to its progression to EA. Many discrepancies, however, have been highlighted in the literature when comparing human observations with previous animal models,1,5-10 including the devel-opment of benign tumor and adenosquamous tumors observed rarely in humans, a low rate of EA tumorigenesis despite deliberate esophageal exposure to extensive gastroesophageal reflux, and no apparent impact of duration of the exposure on the incidence of BE/EA. The absence of any tumoral dissemination to regional lymph nodes or distant organs also questions whether the induced malignancies behave in an aggressive manner. It has also been questioned whether creeping of the duodenal mucosa or entrapment of the jejunal mucosa may be the mechanisms to be involved in the development of BE rather than a de novo process. As reported by others,8,9 the high postoperative mortality despite the well-known expertise of the surgical team raised ethical concerns and questioned the reprodu-cibility of such modeling.

In humans, BE metaplasia is thought to result from the abnormal differentiation of esophageal stem cells or from the transdifferentiation of 1 mature esophageal cell type into another type of mature cell.26The gene expression profile of TFF in a rodent model with EJ anastomosis suggests that BE occurs de novo and is not owing to proximal migration of jejunal mucosa.17Brunner glands in the DRG group and observation of short segments of BE surrounded by squamous mucosa suggest that BE-like lesions in the rat model could arise also from duodenal mucosa through entrap-ment or creeping in accordance with previous studies.8,9 Only a formal lineage tracing would allow to solve this question definitely. Contrary to our results, some investigators7,9,11have suggested that the time of exposure to reflux may determine the type and incidence of lesions that develop; however, the number of rats operated on in each of those studies was relatively small.6,8,11

The incidence of EA in the present study was low (13%) with some adenosquamous tumors occurring despite avoiding the use of nitrosa-mines, a co-carcinogen shown to be responsible for high rates of a squamous cell tumoral compo-nent.27A review has discussed the reproducibility of the rat model28with regard to (i) the variability of the operative procedures, with a greater rate of EA after EJ than after ED anastomosis,3,13possibly because of a lesser volume of refluxate in the latter type of anastomosis,29(ii) the various durations of reflux, (iii) the use of a variety of rat species, and (iv) the suboptimal pathologic analysis of induced lesions.8

Analysis of the transcriptome allowed us to identify genes that had been shown to previously be important in human EA, corroborating the validity of this model.15,30,31Moreover, this analysis allowed us to identify novel, potential biomarkers involved in esophageal carcinogenesis. First, the S100a4 gene, whose protein is known to have many roles in cancer cell properties, was upregulated.32 We reported previously that altered properties of OE33 esophageal cancer cells deficient for MUC4 mucin correlated with that of the calcium-binding protein s100A4,2 suggesting that regulation of S100A4 by the membrane-bound mucin MUC4 would lead to decreased proliferation and migration of esophageal cancer cells.

MCM6 and CHEK2, both involved in cell proliferation, were up regulated in our transcrip-tomic study, and activity on cell proliferation was confirmed in vitro. MCM6 has been shown previously to be involved in meningioma, and its expression was correlated with clinical outcomes and grade of the tumor.21 As for CHEK2, a gene mutation has been associated with an increased risk of breast cancer.22Altogether, our results and those in the literature suggest strongly that MCM6 and CHEK2 may play an important roles in the properties of esophageal adenocarcinomatous cells as well as in esophageal carcinogenesis. Table II. Distribution of histologic lesions according to the duration of reflux exposure in rats

Reflux group

Time of exposure to reflux (in weeks)

21–30 30–50 50–83

DGER group DER group DGER group DER group DGER group DER group Histologic results

Esophagitis only 6 (50%) 2 (25%) 11 (55%) 9 (64%) 15 (48%) 11 (48%) BE only 3 (25%) 5 (62%) 4 (20%) 4 (28%) 8 (26%) 11 (48%) Dysplasia or EA 3 (25%) 1 (13%) 5 (25%) 1 (8%) 8 (26%) 1 (4%) Total 12 (100%) 8 (100%) 20 (100%) 14 (100%) 31 (100%) 23 (100%)

BE, Barrett’s esophagus; EA, esophageal adenocarcinoma.

Surgery Volumej, Number j Gronnier et al 11 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358

(16)

Tsg101 was shown previously to decrease proliferation in breast cancer.23 Accordingly, our results in esophageal cancer cells deficient for Tsg101 showed decreased proliferation, suggesting that Tsg101 is a new and interesting marker for further study in that type of cancer.

The respective contributions of the duodenal and gastroduodenal reflux on the development of BE and EA remain controversial.5,7,9,12We wanted to evaluate the impact of the gastric and the duodenal contents on the carcinogenic sequence. The pH of gastric juice has been shown previously to be neutralized when an EJ anastomosis is performed without gastrectomy33; therefore, we chose to perform an ED anastomosis.6,28 We showed that absence of gastric juice (DER group) was associated with significantly earlier lesions of BE, whereas combined gastric and duodenal reflux (DGER group) was associated with more advanced lesions (dysplasia and EA). A control group of rats exposed to mixed reflux and receiving pharmaco-logic acid suppression (PPI group) confirmed this mechanism with a dramatic decrease in the number of early lesions. Confirming data reported previously using a cellular model of EA, these results suggest a distinct impact of the duodenal reflux according to pH environment,34 which suggests that PPIs may prevent initiation of the carcinogenic sequence with a protective effect. These results are in accordance with a recently published study,35 but contrary to another36 in which a PPI was administered subcutaneously on alternative days without verification of acid suppression by pH measurements.

Gastric content may act as a catalyst for the carcinogenic process favoring tumor development. When comparing our data with published results from previous, similar rat studies comparing DGER and DER, 3 of 4 studies did not show any differences between groups regarding the occurrence BE or EA but with small number of animals enrolled and lesions not related to reflux.7,9,12The fourth study suggested a protective effect of gastric juice against the development of EA.5

For ethical reasons, we chose to include a limited number of rats in the control groups. In the PPI group, we performed a preliminary analysis at 30 weeks. Because the results were significant, it did not seem ethically valid to continue the study.

In conclusion, despite pathophysiologic differ-ences with humans, the rat ED model reproduces accurately histologic and molecular lesions of the BE carcinogenetic sequence and allowed us

to identify potential tumor-associated proteins that may prove to be new biomarkers and new therapeutic targets in EA. This rat ED anastomosis model offers a unique opportunity to study the respective roles of the duodenal and gastroduo-denal contents in the BE carcinogenic sequence.

C.G. and E.B. equally contributed to the work. I.V.S. and C.M. equally contributed to the work. Supported by La Fondation pour l’Avenir and La Fondation pour la Recherche Medicale (Equipe FRM 2009). Emilie Bruyere is the recipient of a PhD Fellowship from Le Centre Hospitalier Regional Universitaire de Lille and Region Nord-Pas de Calais. Isabelle Van Seuningen is the recipient of a ‘‘Contrat Hospitalier de Recherche Translationnelle’’/CHRT 2010, AVIESAN.

The authors thank Dr Jean-No€el Freund (Inserm U782, Strasbourg) for scientific discussions. We thank also Dr William B Robb for critical reading of this manuscript. This work was supported by grants from CHRU de Lille, Region Nord-Pas-de-Calais, La Fondation de l’Avenir and La Fondation pour la Recherche Medicale (EQUIPE FRM 2009) and AVIESAN (CHRT 2010, IVS).

REFERENCES

1. Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP. Oesophagogastric junction adenocarcinoma: which thera-peutic approach? Lancet Oncol 2011;12:296-305.

2. Hamilton SR, Smith RR. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett’s esophagus. Am J Clin Pathol 1987;87: 301-12.

3. Moore KH, Barry P, Burn J, Falk G. Adenocarcinoma of the rat esophagus in the presence of a proton pump inhibitor: a pilot study. Dis Esophagus 2001;14:17-22.

4. Levrat M, Lambert R, Kirshbaum G. Esophagitis produced by reflux of duodenal contents in rats. Am J Dig Dis 1962; 7:564-73.

5. Ireland AP, Peters JH, Smyrk TC, DeMeester TR, Clark GW, Mirvish SS, et al. Gastric juice protects against the develop-ment of esophageal adenocarcinoma in the rat. Ann Surg 1996;224:358-70.

6. Goldstein SR, Yang GY, Curtis SK, Reuhl KR, Liu BC, Mirvish SS, et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997;18:2265-70.

7. Fein M, Peters JH, Chandrasoma P, Ireland AP, Oberg S, Ritter MP, et al. Duodenoesophageal reflux induces esophageal adenocarcinoma without exogenous carcin-ogen. J Gastrointest Surg 1998;2:260-8.

8. Buskens CJ, Hulscher JB, van Gulik TM, Ten Kate FJ, van Lanschot JJ. Histopathologic evaluation of an animal model for Barrett’s esophagus and adenocarcinoma of the distal esophagus. J Surg Res 2006;135:337-44.

9. Miwa K, Segawa M, Takano Y, Matsumoto H, Sahara H, Yagi M, et al. Induction of oesophageal and forestomach carcinomas in rats by reflux of duodenal contents. Br J Cancer 1994;70:185-9.

10.Li H, Walsh TN, O’Dowd G, Gillen P, Byrne PJ, Hennessy TP. Mechanisms of columnar metaplasia and squamous

ARTICLE IN PRESS

FLA 5.2.0 DTD  SEC CODE: OC

n

YMSY3448_proof  12 June 2013  8:13 am  ce

Surgery j 2013 12 Gronnier et al 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482

(17)

regeneration in experimental Barrett’s esophagus. Surgery 1994;115:176-81.

11. Pera M, Brito MJ, Poulsom R, Riera E, Grande L, Hanby A, et al. Duodenal-content reflux esophagitis induces the development of glandular metaplasia and adenosquamous carcinoma in rats. Carcinogenesis 2000;21:1587-91. 12. Oberg S, Wenner J, Johansson J, Walther B, Willen R.

Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 2005;242:49-54.

13. Bonde P, Sui G, Dhara S, Wang J, Broor A, Kim IF, et al. Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model. J Thorac Cardiovasc Surg 2007;133:763-9.

14. Mariette C, Piessen G, Leteurtre E, Hemon B, Triboulet JP, Van Seuningen I. Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase. Surgery 2008;143:58-71.

15. Piessen G, Jonckheere N, Vincent A, Hemon B, Ducourou-ble MP, Copin MC, et al. Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepa-tocyte nuclear factor 1alpha. Biochem J 2007;402:81-91. 16. Macke RA, Nason KS, Mukaisho K, Hattori T, Fujimura T,

Sasaki S, et al. Barrett’s esophagus and animal models. Ann N Y Acad Sci 2011;1232:392-400.

17. Oh DS, DeMeester SR, Dunst CM, Mori R, Lehman BJ, Kuramochi H, et al. Validation of a rodent model of Barrett’s esophagus using quantitative gene expression profiling. Surg Endosc 2009;23:1346-52.

18. Fitzgerald RC. Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut 2006;55:1810-20. 19. Zagorowicz E, Jankowski J. Molecular changes in the

progression of Barrett’s oesophagus. Postgrad Med J 2007; 83:529-35.

20. van der Sluis M, Melis MH, Jonckheere N, Ducourouble MP, B€uller HA, Renes I, et al. The murine Muc2 mucin gene is transcriptionally regulated by the zinc-finger GATA-4 transcription factor in intestinal cells. Biochem Biophys Res Commun 2004;325:952-60.

21. Gauchotte G, Vigouroux C, Rech F, Battaglia-Hsu SF, Soudant M, Pinelli C, et al. Expression of minichromo-some maintenance MCM6 protein in meningiomas is strongly correlated with histologic grade and clinical outcome. Am J Surg Pathol 2012;36:283-91.

22. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002;71:432-8.

23. Zhang Y, Song M, Cui ZS, Li CY, Xue XX, Yu M, et al. Down-regulation of TSG101 by small interfering RNA inhibits the proliferation of breast cancer cells through the MAPK/ERK signal pathway. Histol Histopathol 2011;26:87-94.

24.Bruyere E, Jonckheere N, Frenois F, Mariette C, Van Seunin-gen I. The MUC4 membrane-bound mucin regulates esoph-ageal cancer cell proliferation and migration properties: Implication for S100A4 protein. Biochem Biophys Res Com-mun 2011;413:325-9.

25.Su Y, Chen X, Klein M, Fang M, Wang S, Yang CS, et al. Phenotype of columnar-lined esophagus in rats with esoph-agogastroduodenal anastomosis: similarity to human Bar-rett’s esophagus. Lab Invest 2004;84:753-65.

26.Eberhard D, Tosh D. Transdifferentiation and metaplasia as a paradigm for understanding development and disease. Cell Mol Life Sci 2008;65:33-40.

27.Mirvish SS. Studies on experimental animals involving sur-gical procedures and/or nitrosamine treatment related to the etiology of esophageal adenocarcinoma. Cancer Lett 1997;117:161-74.

28.Attwood SE, Harrison LA, Preston SL, Jankowski JA. Esoph-ageal adenocarcinoma in ‘‘mice and men’’: back to basics!. Am J Gastroenterol 2008;103:2367-72.

29.Sato T, Miwa K, Sahara H, Segawa M, Hattori T. The sequen-tial model of Barrett’s esophagus and adenocarcinoma induced by duodeno-esophageal reflux without exogenous carcinogens. Anticancer Res 2002;22:39-44.

30.Song S, Guha S, Liu K, Buttar NS, Bresalier RS. COX-2 in-duction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett’s oesoph-agus and oesophageal adenocarcinoma. Gut 2007;56:1512-21.

31.Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Re-iter R, Feith M, et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 2006;59:631-4.

32.Sherbet GV, Lakshmi MS. S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis. Anti-cancer Res 1998;18:2415-21.

33.Fein M, Fuchs KH, DeMeester TR, Peters JH, Wittmann D, Weig M. Evaluation of the intestinal microflora in the rat model for esophageal adenocarcinoma. Dis Esophagus 2000;13:39-43.

34.Kaur BS, Ouatu-Lascar R, Omary MB, Fang M, Wang S, Yang CS, et al. Bile salts induce or blunt cell proliferation in Bar-rett’s esophagus in an acid-dependent fashion. Am J Physiol Gastrointest Liver Physiol 2000;278:1000-9.

35.Miyashita T, Shah FA, Marti GP, Wang J, Bonde P, Gibson MK, et al. Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical model. Dig Dis Sci 2011;56:1309-14.

36.Nasr AO, Dillon MF, Conlon S, Downey P, Chen G, Ireland A, et al. Acid suppression increases rates of Barrett’s esophagus and esophageal injury in the presence of duodenal reflux. Surgery 2012;15:382-90.

Surgery Volumej, Number j Gronnier et al 13 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606

(18)

Our reference:

YMSY 3448

P-authorquery-v9

AUTHOR QUERY FORM

Journal:

YMSY

Article Number:

3448

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consulthttp://www.elsevier.com/artworkinstructions.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof.

Location in article

Query / Remark: Click on the Q link to find the query’s location in text Please insert your reply or correction at the corresponding line in the proof

If there are any drug dosages in your article, please verify them and indicate that you have done so by initialing this query

Q1 Please check heading levels throughout to ensure that they are correct.

Q2 Please confirm that given names and surnames have been identified correctly.

Q3 For figure 3A/D, the resolution is too low to be used. Please provide better quality figure of 300 dpi.

EQ1 Figure 5: ‘***’ not defined at caption. Kindly check and provide.

Please check this box or indicate your approval if you have no

corrections to make to the PDF file

,

Figure

Fig 1. Macroscopic aspect of specimens classified according the operation group and histologic observation of the esophagus after operation using hematoxylin and eosin, Safran, and Astra blue stainings
Table II. Distribution of histologic lesions according to the duration of reflux exposure in rats

Références

Documents relatifs

dont la cause n’est pas rapidement retrouvée doit faire évoquer un RGO, à plus forte raison doit faire évoquer un RGO, à plus forte raison s’il s’accompagne

pylori eradication increases the risks of Barrett's esophagus and esophageal adenocarcinoma, and does not influence the risk of esophageal squamous cell carcinoma,

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients

Plusieurs éléments soutiennent cette hypothèse, dont l’existence de micro-inhalations du contenu gastrique au cours de la FPI, leur effet délétère sur le parenchyme pulmonaire,

Note that, if H is a (notnormal) subgroup of odd prime index in the solvable group G, then G=L does have the structure of a Frobenius group with Frobenius complement H=L (in

La pH­impédancemétrie œsophagienne réalisée sous IPP permet de rechercher la persistance d’un reflux pathologique acide ou peu acide Les symptômes évoquant un RGO, résistants à

Cette technique a fait l’objet d’une étude nord-américaine (119 pts), qui a permis son approbation par la FDA. Dans une publication initiale dans Gastrointestinal Endoscopy

L’association d’un ulcère gastrique, d’un ulcère bulbaire compliqué ou résistant au traitement médical, la survenue de reflux gastro œsophagien chez les gastrectomisés